discover Edinburgh Health Informatics
Lead Research Organisation:
University of Edinburgh
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
- University of Edinburgh (Lead Research Organisation)
- Hua Xia Healthcare Holdings Ltd (Collaboration)
- Skythians Educational Trust Limited (Collaboration)
- EU Knowledge and Innovation Community for Information and Communication Technologies (EIT Digital) (Collaboration)
- NHS National Services Scotland (NSS) (Collaboration)
- ShenZhen People’s Hospital (Collaboration)
- Vishuo Biomedical Pte Ltd (Collaboration)
- Shenzhen University (Collaboration)
People |
ORCID iD |
Publications
Stock SJ
(2021)
The international Perinatal Outcomes in the Pandemic (iPOP) study: protocol.
in Wellcome open research
| Description | Edinburgh Data Science |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | P2D has supported EDS - a cross university integration activity that coordinates data intensive research, innovation and training across disciplines. EDS launched a full Masters in Medical Informatics in September 2016. |
| Description | Guangdong Province FAO |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Description | Guangdong Province FAO return visit |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Description | Guangdong Province Party Secretary visit |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Description | Innovative Healthcare Delivery Programme |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | P2D supports IHDP with its aim to translate cutting edge research and innovation into measurable health and wealth gains for patients and populations. IHDP is currently focused on delivering solutions for cancer patients. The opportunity is for NHS Scotland is to build upon recent developments in informatics, data analytics, digital health and precision medicine. IHDP has secured over a £1 million in Scottish Gobvernment funding to pursue its work. |
| Description | Nick Mackie Scottish Parliament Cross Party Group on China |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | P2D Parliamentary Visit by Ash Denham MSP |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Description | 3 Famous Project - International Diabetes Centre |
| Amount | £200,000 (GBP) |
| Organisation | Government of China |
| Sector | Public |
| Country | China |
| Start | 02/2018 |
| End | 03/2022 |
| Description | Scottish Dementia Informatics Platform (SDIP) |
| Organisation | NHS National Services Scotland (NSS) |
| Department | Scottish Dementia Informatics Platform |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Supporting the salary of an project manager to help set up the SDIP vision. |
| Collaborator Contribution | Scottish Dementia Informatics Platform, a major Scottish initiative to pull all key care information for dementia onto a single platform to improve clinical care, service design and brain health research - multiple pharma companies involved in the partnership (SMSA-ID, Arhidia, MSD, Biogen, Eli Lilly) |
| Impact | SDIP involves collaboration between many companies - University of Edinburgh, Alzheier's Scotland, Stratified Medicines Scotland Innovation Centre, Biogen, Merck (US), Eli Lilly, Janssen, Synapse, Cadgwith Health and Idox Health. In June 18, at Scotland's largest annual dementia conference, the newly created Scottish Brain Health Register was launched. This is being used to gather data from volunteers initially at NHS Lothian with plans in place to bring onboard NHS Tayside, NHS Greater Glasgow and Clyde and NHS Grampian. It is planned that the new register will be used in all memory services across Scotland by 2022, as a key resource for the industrial and academic partners to sign up volunteers to appropriate studies. |
| Start Year | 2017 |
| Description | Skythians |
| Organisation | Skythians Educational Trust Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have initiated a major collaboration with Skythians/National Legionella Centre which involves running a number of workshops followed by the design and building of a database covering health a social welfare in rental properties in the UK. University staff are working with the Skythians team to develop a mobile portal which will capture data on an iPad being used by assessors in the field during routine inspections of UK residential rental properties. |
| Collaborator Contribution | Skythians are providing the expertise to progress this project and run engagement workshops. |
| Impact | The portal which was completed in April 2018 and has been used to start collecting data from 'trial' housing assessments. The ability to showcase the portal has been crucial in helping the company to approach potential investors, as well as new customers, with a credible commercial offering. As a result, NLIC has now received its first major customer (bringing 3000 rental properties) and first investment of over £1m. |
| Start Year | 2017 |
| Description | UoE & HX |
| Organisation | Hua Xia Healthcare Holdings Ltd |
| Country | Hong Kong |
| Sector | Private |
| PI Contribution | expertise in medical informatics, chronic disease management, research, education |
| Collaborator Contribution | Hong Kong listed hospital management and investment company with ambition to collaborate with the Usher Institute across education, research, medical informatics and health service delivery in China. |
| Impact | In November 2016, the partners established the Edinburgh based Institute for Medical Research, Education and Management which will support the development and delivery of healthcare projects in China. Further meetings between the parties were held in China in December 2016 and Abu Dhabi in January 2017. During 2018, UoE-HX continued to collaborate to identify opportunities in China's healthcare market including working together to support the establishment of an International Diabetes Centre in Shenzhen People's Hospital, Shenzhen, Southern China. An IT-Data system is being developed to underpin research and service delivery which is expected to be commissioned in March 2018. |
| Start Year | 2016 |
| Description | UoE & SZPH |
| Organisation | ShenZhen People’s Hospital |
| Country | China |
| Sector | Hospitals |
| PI Contribution | Joint venture formed on 8th March 18. |
| Collaborator Contribution | Joint venture formed on 8th March 18. |
| Impact | A project to establish a bridgehead in China, major contracts are in place with Shenzhen University and Hua Xia Healthcare Limited. Two Chinese subsidiary companies have been formed, one to provide medical informatics training and education to Shenzhen University, and a second to establish a Shenzhen city wide clinical network to manage diabetes across Guangdong Province. JV formed 8th March 2018 - called Edinburgh International Investments Ltd with 2 subsdiaries in Mainland China. Currently servicing the Shenzhen People's Hospital project (above) and establishing a 200 bed hospital in Putian, Fujian Province with a focus on diabetes, chronic disease management, paediatrics, maternity services, medical training, clinicla research and medical informatics. |
| Start Year | 2016 |
| Description | UoE - EIT Digital |
| Organisation | EU Knowledge and Innovation Community for Information and Communication Technologies (EIT Digital) |
| Country | Hungary |
| Sector | Private |
| PI Contribution | P2D catalysed the collaboration between the Farr Institute, Aridhia, BT and Italy;s Reply & Engineering, the Universities of Edinburgh and Trato with local and national medical informatics network and knowledge |
| Collaborator Contribution | Commercial and academic approaches to develop a commercially viable route for provision of medical / healthcare data safe havens across Europe. |
| Impact | no outcomes yet - work in progreess |
| Start Year | 2015 |
| Description | UoE-SZU |
| Organisation | Shenzhen University |
| Country | China |
| Sector | Academic/University |
| PI Contribution | sharing advice / experience with a view to forming a collaboration |
| Collaborator Contribution | sharing advice / experience with a view to forming a collaboration |
| Impact | P2D has been instrumental in shaping this relationship, A Heads of Terms was signed in November 2016 followed by meetings in Shenzhen in December 2016. |
| Start Year | 2016 |
| Description | UoE-Vishou |
| Organisation | Vishuo Biomedical Pte Ltd |
| Country | Singapore |
| Sector | Private |
| PI Contribution | exchanging advice |
| Collaborator Contribution | exchanging advicer |
| Impact | discussions in progress, no outcomes as yet |
| Start Year | 2015 |
| Description | 19 January 2021 Cross-Party Group on Life Sciences: "Focus on the economic impact of the pharmaceutical industry and healthcare data". ABPI - |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | N/A |
| Year(s) Of Engagement Activity | 2021 |
| Description | Attendance at BioData World Congress 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | An interesting and participatory conference supporting the wider campaign at IGMM seeking opportunities in data in biomedicine. Some useful contacts a leads to follow up (primarily by Andrea). There have been some referral follow ups also to the QTL group with one potential collaboration in discussion at this time. Clear that pharma and other commercial companies currently have access to very large amounts of data, much of it (e.g. GWAS summary stats) from open sources or from their own projects (e.g. clinical trials). Connected devices are increasingly a source of data, including monitoring responses to treatment at an individual level - the field is not constrained by generating data. Many good (and high profile) speakers. Approximately 200 attendee's majority industry. UoE roundtable "Electronic Health Records and genomics research in consented populations" went well and provided a useful way to interact subsequently with those attending (11 plus the two moderators). Key contacts/networking included : Karen Temple (Professor of Medical Genetics, Co-lead of the Wessex Genome Medicine Centre); Matt Sims (MRC Epidemiology Unit); Algy Taylor (CGM Manchester); Jonathan Mangion (?Bioinformatics, Thermo Fisher); Craig McCallum (SMS-IC); David Pulford (GSK); Matthieu-P Schapranow (Hasso-Plattner Inst) |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.terrapinn.com/conference/biodata/index.stm |
| Description | BioData World Congress |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | An interesting and participatory conference supporting the wider campaign at IGMM seeking opportunities in data in biomedicine. Some useful contacts a leads to follow up (primarily by Andrea). There have been some referral follow ups also to the QTL group with one potential collaboration in discussion at this time. Clear that pharma and other commercial companies currently have access to very large amounts of data, much of it (e.g. GWAS summary stats) from open sources or from their own projects (e.g. clinical trials). Connected devices are increasingly a source of data, including monitoring responses to treatment at an individual level - the field is not constrained by generating data. Many good (and high profile) speakers. Approximately 200 attendee's majority industry. UoE roundtable "Electronic Health Records and genomics research in consented populations" went well and provided a useful way to interact subsequently with those attending (11 plus the two moderators). Key contacts/networking included : Karen Temple (Professor of Medical Genetics, Co-lead of the Wessex Genome Medicine Centre); Matt Sims (MRC Epidemiology Unit); Algy Taylor (CGM Manchester); Jonathan Mangion (?Bioinformatics, Thermo Fisher); Craig McCallum (SMS-IC); David Pulford (GSK); Matthieu-P Schapranow (Hasso-Plattner Inst) etc |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.terrapinn.com/conference/biodata/index.stm |
| Description | Biotech Showcase |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A 3 day investor and partnering conference on 8-10 January in San Francisco to allow private and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives. 15 leads came out of the conference and three remain ongoing albeit at early stages, one with the Harrington Discovery Institute Research in Ohio, one with VU University Medical Centre in Amsterdam and a third with O2H in Cambridge. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Chair Scottish Government COVID-19 CMO Advisory Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | N/A |
| Year(s) Of Engagement Activity | 2020,2021,2022 |
| Description | Chair Scottish Government Committee Pandemic Preparedness |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | N/A |
| Year(s) Of Engagement Activity | 2022 |
| Description | Edinburgh Diabetes Day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | N/A |
| Year(s) Of Engagement Activity | 2020 |
| Description | Frontier's Meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Arranging a Frontiers Meeting bringing together academia, patients, industry and NHS to explore ways in which data science and machine learning can improve health care for those with long-term conditions, using asthma as an exemplar. We intend to identify key points of interest from the various perspectives at the meeting and look at mechanisms for future collaboration and funding. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Integrating person/patient-generated data with electronic health records |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Designed to bring relevant academics and industrialist together to facilitate the meaningful integration of patient-collected data within electronic health records. The thinkathon was attended by over 20 academics and companies (Cerner, iSOFT, IBM, Phillips, e-Redbook, BabylonHealth, HealthUnlocked). An application surrounding entrepreneurship and collaboration with industry is currently being written for the University of Edinburgh Data Driven Innovation Programme. |
| Year(s) Of Engagement Activity | 2018 |
| Description | MHRA Repurposing Talk |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dan O'Connor from the UK MHRA was invited to give a joint seminar for academics and industrialists on data related to drug repurposing, followed by a networking event. Attracting over 100 attendees from business, the NHS and Universities. Excellent opportunity for networking between academics and industry. 16 companies attended (Clintec, Roslin CT, Aquila Biomedical, LifeArc, GSK, Calcivis, Edinburgh Molecular Imaging, Medpace, PPD, Charles River Laboratories, ICON Clinical Research, IoMET, Carnegie Clinical Research Ltd, NeurocentRx, Innovative Healthcare Delivery Programme, Roslin Cells). |
| Year(s) Of Engagement Activity | 2018 |
| Description | Oshi Inc / UoE PREdiCCt team Workshop |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A face to face meeting with the software developer team of OSHI to tailor the consumer IBD App for use in the PREdicCt study. A collaborative agreement of $460k is currently being finalised between the Uni and OSHI to onward fund the clinical trial using the new specifically designed OSHI App to collect patient observational data over a 2 year period using patients own mobile devices. This data will be collated to attempt to identify any patient triggers scientifically. The agreement will be signed imminently & funding will start Dec 1st 2018. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Participant UK Government SAGE |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Through the Data and Connectivity NCS, HDRUK convened weekly then fortnightly calls bringing together the national health data community to report on emerging insights and data needs. A regular report was submitted to SAGE with most recent research insights and update on health data available via the national TREs |
| Year(s) Of Engagement Activity | 2020,2021,2022 |
| Description | Robotics in Healthcare: current issues and future trends |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Background: The emergence of robotics and artificial intelligence (AI) is transforming industries around the world. Robot technologies are evolving exponentially, particularly as they converge with other functionalities such as AI to learn from their environment, from each other, and from humans. There is now also increasing automation of healthcare services, where robots have begun to solve individual aspects of human performance such as precision (e.g. surgical robots), logistic/mechanical tasks that do not require complex cognitive human input (e.g. service robots), and complex cognitive tasks (e.g. rehabilitation robots). However, there are increasing concerns relating to the effective integration of robots with their social environment in healthcare settings, particularly in relation to applications that not only augment but also replace human capabilities. Aim: To explore existing and anticipated future opportunities and challenges (including social, technical, commercial, and legal) associated with integration of robotics in healthcare. Relevant experience: This proposal is a collaboration between The Business School and The Usher Institute. The proposed work builds on important foundational work including significant experience in arranging multi-stakeholder workshops and round-table discussions, recent collaborations with industry in the UK (e.g. ROWA Technologies, Cambridge Medical Robotics, IBM Watson, Swisslog, Intuitive Surgical, Softbank Group, InTouch Health, Robosoft) and research centres (Edinburgh Centre for Robotics), and recent qualitative work exploring international social, legal and technical challenges associated with robotics and AI. Our work to date has shown that technological challenges are likely to be addressed over time as robotic capabilities develop. More importantly, a range of sociotechnical challenges are hampering progress (i.e. negative publicity of robots amongst healthcare professionals, conflicting views on the appearance of robotic applications, reconfiguration of roles and responsibilities, and new ethical and legal challenges). We would now like to work with industry to identify solutions to these challenges and identify approaches to facilitate the meaningful integration of robotics into their social environments. Proposed method: We (Hajar Mozaffar, Kathrin Cresswell, and Aziz Sheikh) propose to hold an AIMDay event (in April/May), bringing together participants from industry and academia to encourage interdisciplinary collaboration. AIMDays bring understanding and new perspectives to existing challenges of organisations. Drawing on this method, we plan to invite industry to highlight issues around sociotechnical problems (around academically discovered themes) in integration of robotics into health settings and invite scientists and experts from several different disciplines to gather and find ways to approach the problems. We have already liaised with AIMDay organisers for co-ordination and set up of the event. We will also aim to draw on this format to collect more formal qualitative research data, which we will analyse and prepare for publication. Participants: The AIMDay format will provide new disruptive expertise in linking a range of stakeholders including industry (AI and robotics developers) and academia (with expertise in sociotechnical aspects of technology). We aim to recruit approximately 15 participants from our existing networks and these will represent a range of geographical locations. Expected outcomes: This funding is expected to develop and enhance close and productive collaborations between industry and academia in order to address the technological, social, and organisational progress in tandem. The AIMDay will help to form a partnership between representatives of industry and academia (in different disciplines) with the intention of developing grant applications to identify opportunities and capture value from innovations in robotics and AI for healthcare purposes. (e.g. MRC, Industry Challenge Strategy Fund, Knowledge Transfer ). |
| Year(s) Of Engagement Activity | 2018 |
| Description | Science at the Interface to Industry |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | A 3 day event on 17-19 April for PhD students focussing on the skills to interface their research with industry and to explore the role of scientists in the biotechnology and pharmaceutical industries. The event was held at the Institute of Genetics and Molecular Medicine and organised by Nick Gilbert of the MRC Human Genetics Unit and Andy McCallion of John Hopkins University, Baltimore, USA. Companies involved in the events included Epidarex Capital, Mars PetCare, NeurocentRx Ltd, New England Biolabs, and Parkure Ltd. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Translational Research at University of Edinburgh (TRUE) |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Rationale A key Strategic Aim of the University of Edinburgh is to increase Industry engagement to: • catalyse scientific translation and medical advances • provide a key source of revenue via collaboration & consultancy Biotechnology and Pharmaceutical companies have acknowledged that their internal R&D processes have been failing to produce novel, efficacious and safe therapies, recognising the need to increase partnerships with leading Universities. In the College of Medicine and Veterinary Medicine (CMVM) we have world-recognised research excellence in basic and clinical science. Consequently, the CMVM and its outstanding body of researchers, infrastructure and capabilities have a unique opportunity to capitalise on the current situation (Fallowfield, J. The researcher of the futureengages with industry. Lancet. 2013;381 S1:S7-8). Aims To develop an outward-facing, commercially-relevant 'identity' for the key research 'pillars of excellence' for the CMVM, in order to more effectively promote the Experimental and Translational Medicine Research expertise, capabilities and opportunities in Edinburgh. By developing a translational research 'identity', that fits within corporate branding and the College's marketing hierarchy, but which reflects the language and aligns with the therapeutic approach of BioPharma, we aim to enhance and increase: • Collaborative research • Consulting/Service research • Overall awareness to additional stakeholders e.g. funders, donors, patients & patient advocacy groups Market research was undertaken across the biotech and pharmaceutical industry and the information gathered was used to design and build the website in consultation with a local company (EDINA Ltd). Beta testing is currently underway with industrial partners. |
| Year(s) Of Engagement Activity | 2014,2018 |
| Description | Unlocking Better Health Outcomes - Digital Catapult Centre |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prof Caroline Hayward attended this event in London on 12th-13th December at the Digital Catapult Centre, London. Aimed at researchers, experts and small to medium sized companies interested in using digital technologies and Electronic Health Records to improve prevention and diagnosis in healthcare. Companies in attendance included Digi.me, Aviva, Deliotte, Nuffield health, Eagle Genomics, Twyn Brain, Drayson Technologies, Saddle Point Science and Benevolent AI. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.digitalcatapultcentre.org.uk/open-calls/swissrepitstop/ |
| Description | Visit to Buhlmann Lab |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | A mainstay of CF therapy is the use of systemic antibiotics (IV) to treat worsening in clinical symptoms (exacerbation). Targetting antibiotics to the most appropriate patients is presently difficult and anti-biotic resistance is a common feature of advanced CF lung disease. We propose combining calprotectin as a near patient assay with other clinical measurements. By utilising a bioinformatics approach we will be able to create a CF toolkit that allows the predication of need for antibiotics to treat CF exacerbation, specifically targeting those patients that require antibiotics. This will reduce unnecessary antibiotic use and also potentially reduce the length of treatment courses of necessary antibiotics. Buhlmann Labs (Switzerland) that has a Calprotection diagnostic assay kit approved for use in Rhuematoid arthritis and IBD/IBS. Calprotectin biomarker assessment via this kit would be highly effective providing a realtime (it takes 30mins) readout. UoE has approached Buhlmann to gain access to the kit (which is expensive) free of charge to utilise as part of the overall informatics and biomarker combined investigative approach. Funding is requested for RG and research assistant to travel to Buhlmann in Switzerland to meet Face to Face to present to the Buhlmann scientific board and the product management team. Buhlmann Labs is based just outside of Basel, Switzerland |
| Year(s) Of Engagement Activity | 2018 |